We are focusing on a few key molecular pathways including; 1) Polycomb -
mediated epigenetic gene
silencing in the tumor initiation, maintenance, and invasion, 2) c - Met (receptor tyrosine kinase) signal transduction pathways in stemness and migration of these tumor cells, 3) Novel mitogenic signaling pathways that are specific to GSCs, and 4) Identification of radio - and chemo - sensitizing pathway to maximize therapeutic efficacy.
Here, through a genome - wide CRISPR - Cas9 -
mediated forward genetic screen, we identified MORC2 as an essential gene required for
epigenetic silencing by the HUSH complex.